Periprocedural Heparin Bridging in Patients Receiving Vitamin K Antagonists

2012428 citationsReview

Authors

Deborah Siegal · Henry Ford Hospital

Jovana Yudin · Henry Ford Hospital

Scott Kaatz · Henry Ford Hospital

James D. Douketis · Henry Ford Hospital

Wendy Lim · Henry Ford Hospital

Alex C. Spyropoulos · Henry Ford Hospital

Abstract

Vitamin K antagonist-treated patients receiving periprocedural heparin bridging appear to be at increased risk of overall and major bleeding and at similar risk of thromboembolic events compared to nonbridged patients. Randomized trials are needed to define the role of periprocedural heparin bridging.

Topics & Keywords

Atrial Fibrillation Management and Outcomes Venous Thromboembolism Diagnosis and Management Antiplatelet Therapy and Cardiovascular Diseases

UN Sustainable Development Goals

No poverty

Publication Details

Published in: Circulation

Volume 126, Issue 13, pp. 1630-1639

DOI: 10.1161/circulationaha.112.105221

Field-Weighted Citation Impact: 25.43